Report an error

Spotted something inaccurate in “CD19 Co-Stimulatory Fusion Protein Shows Encouraging Activity with Bispecific Antibody in Phase 1 Trial for Refractory Lymphoma”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.